Use of FDG PET as an imaging biomarker in clinical trials of Alzheimers disease

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 431-439

  Herholz, Karl ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

18F fluorodeoxyglucose; acetylcholine esterase inhibitor; Alzheimers disease; biomarker; cerebral glucose metabolism; clinical trial; FDG; general linear model; MCI; mild cognitive impairment; PET; positron emission tomography; rosiglitazone

Indexed keywords

CELECOXIB; DONEPEZIL; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; INSULIN; LETEPRINIM; PHOSPHATIDYLSERINE; PIRACETAM; PYRITINOL; RIVASTIGMINE; ROSIGLITAZONE;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL SUPPORT; STANDARDIZATION; STUDY DESIGN;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84865510355     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.51     Document Type: Review

References (59)

1. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007). (Pubitemid 47058377)
2. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 263-269 (2011). Describes the importance of imaging biomarkers for new diagnostic criteria.
3. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 270-279 (2011). Defines a new diagnostic category and describes biomarkers to identify patients with mild cognitive impairment who have a high likelihood of underlying Alzheimer's disease.
4. Vellas B, Andrieu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 6(1), 56-62 (2007). (Pubitemid 44880273)
5. Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J. Neurochem. 29(1), 13-26 (1977). (Pubitemid 8150483)
6. Hyder F, Patel AB, Gjedde A, Rothman DL, Behar KL, Shulman RG. Neuronal-glial glucose oxidation and glutamatergic-GABAergic function. J. Cereb. Blood Flow Metab. 26(7), 865-877 (2006). (Pubitemid 43980402)
7. Valla J, Yaari R, Wolf Ab et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis. 22(1), 307-313 (2010).
8. Karow DS, McEvoy LK, Fennema-Notestine C et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 256(3), 932-942 (2010).
9. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42(1), 85-94 (1997). (Pubitemid 27304784)
10. Berent S, Giordani B, Foster N et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J. Psychiatr. Res. 33(1), 7-16 (1999). (Pubitemid 29052126)
11. Perneczky R, Hartmann J, Grimmer T, Drzezga A, Kurz A. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J. Geriatr. Psychiatry Neurol. 20(2), 84-88 (2007). (Pubitemid 46878178)
12. Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain 121(Pt 9), 1631-1639 (1998). (Pubitemid 28419970)
13. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J. Cereb. Blood Flow Metab. 5(2), 193-200 (1985). (Pubitemid 15123204)
14. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69(9), 871-877 (2007). (Pubitemid 47329586)
15. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J. Nucl. Med. 53(1), 59-71 (2012). Provides a comprehensive literature overview on the diagnostic uses of FDG PET.
16. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 36(7), 1238-1248 (1995). Describes a popular software tool to facilitate the diagnostic use of FDG PET.
17. Signorini M, Paulesu E, Friston K et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage 9(1), 63-80 (1999). (Pubitemid 29369342)
18. Herholz K, Salmon E, Perani D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17, 302-316 (2002). First multicenter study to discriminate between Alzheimer's disease and controls using user-independent automated analysis of FDG PET.
19. Kakimoto A, Kamekawa Y, Ito S et al. New computer-aided diagnosis of dementia using positron emission tomography: brain regional sensitivity-mapping method. PLoS One 6(9), e25033 (2011).
20. Chen K, Ayutyanont N, Langbaum JB et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 56(1), 52-60 (2011).
21. Landau SM, Harvey D, Madison CM et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32(7), 1207-1218 (2011). Systematic longitudinal analysis of Alzheimer's Disease Neuroimaging Initiative FDG PET data.
22. Caroli A, Prestia A, Chen K et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J. Nucl. Med. 53(4), 592-600 (2012). Analysis of quantitative biomarkers derived from FDG PET in three large independent multicenter datasets.
23. Forster S, Grimmer T, Miederer I et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol. Psychiatry 71(9), 792-797 (2011).
24. Walhovd KB, Fjell AM, Brewer J et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am. J. Neuroradiol. 31(2), 347-354 (2010).
25. Landau SM, Harvey D, Madison CM et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75(3), 230-238 (2010).
26. Drzezga A, Grimmer T, Riemenschneider M et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J. Nucl. Med. 46(10), 1625-1632 (2005). (Pubitemid 46211586)
27. Anchisi D, Borroni B, Franceschi M et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 62(11), 1728-1733 (2005). (Pubitemid 41626670)
28. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159(5), 738-745 (2002). (Pubitemid 34465046)
29. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early Type 2 diabetes. Arch. Neurol. 68(1), 51-57 (2011). 439 www.futuremedicine.com
30. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J. Neural Transm. 109(3), 341-360 (2002). (Pubitemid 34251638)
31. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5(5), 347-360 (2004). (Pubitemid 38568496)
32. Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol. Aging 33(4), 828 e19-e30 (2012).
33. Chen Y, Wolk DA, Reddin JS et al. Voxel-level comparison of arterial spinlabeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 77(22), 1977-1985 (2011).
34. Powers WJ, Perlmutter JS, Videen TO et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology 42(4), 765-770 (1992).
35. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia 5(1), 36-41 (1994). (Pubitemid 24022692)
36. Aisen PS, Andrieu S, Sampaio C et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76(3), 280-286 (2011).
37. Fox NC, Black RS, Gilman S et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64(9), 1563-1572 (2005). (Pubitemid 40617692)
38. Tzimopoulou S, Cunningham VJ, Nichols TE et al. A multi-center randomized proof-ofconcept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J. Alzheimers Dis. 22(4), 1241-1256 (2010). Exemplary study employing rigorous statistical methods for regional image data analysis.
39. Chumbley JR, Friston KJ. False discovery rate revisited: FDR and topological inference using Gaussian random fields. Neuroimage 44(1), 62-70 (2009).
40. Forster S, Buschert VC, Buchholz HG et al. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease. J. Alzheimers Dis. 25(4), 695-706 (2011).
41. Heiss WD, Hebold I, Klinkhammer P et al. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J. Cereb. Blood Flow Metab. 8(4), 613-617 (1988).
42. Tune L, Tiseo PJ, Ieni J et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am. J. Geriatr. Psychiatry 11(2), 169-177 (2003). (Pubitemid 36254190)
43. Craft S, Baker LD, Montine TJ et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69(1), 29-38 (2011).
44. Klinkhammer P, Szelies B, Heiss WD. Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer's disease. Dementia 1, 197-201 (1990).
45. Heiss WD, Kessler J, Mielke R, Szelies B, Herholz K. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. Dementia 5(2), 88-98 (1994). (Pubitemid 24092440)
46. Nordberg A, Lilja A, Lundqvist H et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol. Aging 13(6), 747-758 (1992). (Pubitemid 23010802)
47. Smith GS, Laxton AW, Tang-Wai DF et al. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch. Neurol. doi:10.1001/archneurol.2012.590 (2012) (Epub ahead of print).
48. Wienhard K, Pawlik G, Herholz K, Wagner R, Heiss WD. Estimation of local cerebral glucose utilization by positron emission tomography of [18F]2-fluoro-2-deoxy-dglucose: a critical appraisal of optimization procedures. J. Cereb. Blood Flow Metab. 5(1), 115-125 (1985). (Pubitemid 15146566)
49. Zanotti-Fregonara P, Fadailiel M, Maroy R et al. Comparison of eight methods for the estimation of the image-derived input function in dynamic [18F]-FDG PET human brain studies. J. Cereb. Blood Flow Metab. 29(11), 1825-1835 (2009).
50. Phelps ME, Mazziotta JC, Kuhl DE et al. Tomographic mapping of human cerebral metabolism visual stimulation and deprivation. Neurology 31(5), 517-529 (1981). (Pubitemid 11126262)
51. Potkin SG, Anand R, Fleming K et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol. 4(3), 223-230 (2001). (Pubitemid 34101518)
52. Potkin SG, Alva G, Keator D, Carreon D, Fleming K, Fallon JH. Brain metabolic effects of Neotrofin in patients with Alzheimer's disease. Brain Res. 951(1), 87-95 (2002). (Pubitemid 35253901)
53. Teipel SJ, Drzezga A, Bartenstein P, Moller HJ, Schwaiger M, Hampel H. Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl.) 187(1), 86-94 (2006). (Pubitemid 43876920)
54. Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated FDG PET score as a biomarker for progression in Alzheimer's disease and mild cognitive impairment. J. Nucl. Med. 52, 1218-1226 (2011).
55. Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol. Aging 31(8), 1481-1492 (2010).
56. Mega MS, Dinov ID, Porter V et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F 18 positron emission tomographic study. Arch. Neurol. 62(5), 721-728 (2005). (Pubitemid 40656086)
57. Stefanova E, Wall A, Almkvist O et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J. Neural Transm. 113(2), 205-218 (2006). (Pubitemid 43121756)
58. Small GW, Siddarth P, Silverman DH et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am. J. Geriatr. Psychiatry 16(12), 999-1009 (2008).
59. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapp. 2(4), 189-210 (1995). (Pubitemid 124008664)